Slide 1: A World Without Anesthesia-Related Complications
A WORLD WITHOUT ANESTHESIA-RELATED COMPLICATIONS On a mission to eliminate anaesthesia and respiratory related complications. Philip Siberg, CEO Aug 2023
Slide 2: This is Senzime
This is Senzime 1 A global medical technology company driving innovation and a digital technology shift within monitoring - addressing markets exceeding 50 billion SEK. 2 Superior solutions with at eliminating life-threating anesthesia- andlegacy from Mayo Clinic and Massachusetts General Hospital a
Slide 3: Strong growth and expansion phase with focus on US, Europe and Japan
Strong growth and expansion phase with focus on US, Europe and Japan Market opportunity: 64,000 Operating Rooms and 30 million procedures Market opportunity: 64,000 Operating Rooms and 30 million procedures 50,000 Operating Rooms Licensing partners and 15 million procedures Distribution partners Lic
Slide 4: Standardized use of paralytic drugs creates a significant medical need for accurate patient monitoring
Standardized use of paralytic drugs in anaesthesia create a significant medical need for accurate patient monitoring 22 million patients suffer every year from complications as a result of inadequate monitoring The triad of general from the use of Paralytic Drugs in the OR, highlighting the signific
Slide 5: Senzime leads the new, digital and EMG-based neuromuscular monitoring market
Senzime leads the new, digital and EMG- based neuromuscular monitoring market Objective, digital and 2020’s → accurate monitoring THE NEW GOLD STANDARD, EMG EMG-based monitoring • Digital for high clinical precision • User friendly and cost efficient • Advanced algorithms with high barriers to entry
Slide 6: The Senzime TetraGraph System - the new Gold Standard in Neuromuscular monitoring
The Senzime TetraGraph System - the new Gold Standard in “Helping the anesthesiologist Neuromuscular monitoring secure the right dose of paralytics and indicate when its safe for the TetraGraph® is a Train-of-Four monitor that digitally and objectively follows patient to breathe again.” the patient'
Slide 7: Substantial support for the TetraGraph in international clinical guidelines
Substantial support for the TetraGraph in international clinical guidelines 2022 European Society Anesthetists (ESA) 2021 guidelines EI Grupo Espanol de 2020 Rehabilitacion Multimodal Canadian 2019 Anesthesiology Society Italian Society of Anesthesia, Analgesia, 2018 Reanimation and Consensus Statem
Slide 8: Once-in-a-decade opportunity quote
“We’re in the midst of a once-in-a-decade opportunity to become a global leader in algorithm-powered monitoring solutions that help eliminate anaesthesia and respiratory related complications.”
Slide 9: Senzime's rapid growth rate continues into Q2 2023
Senzimes rapid growth rate continues into Q2 2023 Total revenues Q1+Q2 (kSEK) 1 Net sales for Q2 reached SEK 8.5 m (3.4). Overall growth 149%, monitors 92% and disposables 243% 18 000 +337% 16 000 2 Increased utilization rate of installed TetraGraph 14 000 monitors driving growth 12 000 3 Product mi
Slide 10: Quadrupled sales of disposable sensors drives rapid growth rate and margins
Quadrupled sales of disposable sensors drives rapid growth rate and margins Net sales rolling-12 months Sales of TetraSens consumables, rolling-12 months 28 000 14 000 24 000 12 000 20 000 10 000 16 000 8 000 12 000 6 000 8 000 4 000 4 000 2 000 0 0 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3
Slide 11: Continued expansion of systems drives rapid sales growth and margins
Continued expansion of systems drives rapid sales growth and margins Shipped base of TetraGraph1 Shipped sensors Q1+Q2 (units) 1 800 50 000 1 600 45 000 Installed base 1 400 40 000 drives sales of consum- 35 000 1 200 ables 30 000 1 000 25 000 800 20 000 600 15 000 400 10 000 200 5 000 0 0 Q3 Q4 Q1
Slide 12: Utilization rate increases driven by leading hospital accounts
Utilization rate increases driven by leading hospital accounts Utilization rate, TetraSens per week1 Selected US key accounts 4,5 3,8 3,9 4,0 3,4 3,5 3,2 3,0 2,5 2,5 2,0 2,0 2,0 1,7 1,6 1,6 1,5 1,2 1,0 0,8 0,5 0,0 Q1 2022 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 All deployed accounts Key deployed acc
Slide 13: TetraGraph Customer base July 2023
TetraGraph Customer base July 2023 Number of hospital accounts Jan-May 2023 new account wins Jun-July 2023 new account wins Number of hospital accounts 100+ accounts across end of Q4 ‘22 end of July‘23 Europe Europe 74 22 10 106 US-market 34 6 2 42 10 new accounts across AUS & NZ 3 0 0 3 Europe June
Slide 14: Traction driven by large US customer wins
Traction driven by large US customer wins Accumulated orders of sensors, US hospital 25 000 § XL-account with 90+ TetraGraphs of which 65 so far in use 20 000 § Clinical protocol in place to run TetraGraph on all patients with paralytic agents. § 3-4 months to reach a high utilization rate when 15 0
Slide 15: Analyzing the installed base of TetraGraphs
Analyzing the installed base of TetraGraphs Shipped base status and Top-Tier TetraGraph use rate (patients) Full use (10x per week) 5-y LTV per TetraGraph and utilization rate US (SEK) Ramp-up (+4x per week) 600 000 (2x per week) 500 000 Install phase (1x per week) 400 000 Pending or 300 000 in stoc
Slide 16: Societies advocating for systematic implementation of neuromuscular monitoring
June ‘23: Societies actively advocating for a wide and uantitative monitoring of neuromuscular blockade is vital for patients undergoing anesthesia 2023-06-09, 07:19 systematic implementation of neuromuscular monitoring Quantitative monitoring of neuromuscular blockade is vital for patients undergoi
Slide 17: Key new study results strengthening our case
Key new study results strengthening our case Validating Clinically Important A Quality Improvement Project to Intraoperative electromyographic Prospective evaluation of an Neuromuscular Monitoring Endpoints: Reduce Sugammadex Cost and Waste monitoring in children using a novel enhanced electromyogra
Slide 18: Product market mix and move to in-house production drives gross margin
Product market mix and move to Production in-house in-houseproduction drives gross margin Development of COGS (MSEK) and Gross Margin rolling-12 months (%) 25,0 80,0% 70,0% 68,6% 20,0 64,6% 62,0% 60,0% 57,4% 56,2% 53,7% 54,3% 53,2% 50,0% 15,0 48,2% 40,9% 40,2% 40,0% 10,0 30,0% 16,2 14,6 11,4 11,8 11
Slide 19: OPEX, Earnings, Cash & Directed Issue
OPEX, Earnings, Cash & Directed Issue § Q2 OPEX reduced to 37 101 KSEK (40 035) Ten largest shareholders 30-Jun % Crafoord family 12 506 398 15,1 § Q2 EBITDA increased to -30 201 KSEK (-38 018). Pershing LLC 7 106 707 8,6 § Q2 end of quarter cash amounted to 41 635 KSEK Handelsbanken Fonder AB 6 204
Slide 20: Growth model in reaching +300 mSEK in sales
Growth model in reaching +300 mSEK in sales Direct sales force in US & DE. Clinical support teams driving Delivering the best product Excludes revenues of monitors, Distribution and License utilization – with support of solutions and connectivity to joint Masimo products and partners in 28+ regions
Slide 21: The Senzime 2025 Outlook remains intact
The Senzime 2025 Outlook remains intact New quarterly KPIs Strategy and tactics: Outlook 2025: reported from Q2 2023: § Lead the clinical and technology shift and Net sales estimated to reach § Installed base of TetraGraph is well positioned in a market with a high 1 275 - 325 MSEK by 2025 units and
Slide 22: Management team and Board of Directors
Management team and Board of Directors Philip Siberg GW Hamilton Johanna Tulkki Johanna Faris Adam Dahlberg Eva Walde Jenny Freeman CEO VP Sales US COO DIR of QA&RA Chairman Board Board Fredrik Norrby Anders Selin Anders Jcobsson Slavo Grujicic Göran Brorsson Laura Piccinini Sorin Brull CTO EVP Sale
Slide 23: Wrap-up messages
Wrap-up messages Strong product offerings addressing a clinical and technological large market shift De-risked case in scale-up phase with strong US focus and supported by new clinical guidelines Now driving up utilization of installed TetraGraph base and cost-effectively scaling in focus markets Ba